4.6 Article

Critical role of the WASF3 gene in JAK2/STAT3 regulation of cancer cell motility

期刊

CARCINOGENESIS
卷 34, 期 9, 页码 1994-1999

出版社

OXFORD UNIV PRESS
DOI: 10.1093/carcin/bgt167

关键词

-

类别

资金

  1. National Institutes of Health [CA120510]

向作者/读者索取更多资源

WASF3 has been shown to be required for invasion and metastasis in different cancer cell types and knockdown of WASF3 leads to suppression of invasion/metastasis. Aberrant signaling through the interleukin 6/Janus kinase (JAK)/signal transducer and activator of transcription 3 (STAT3) axis in cancer cells has emerged as a major mechanism for cancer progression. In this study, we demonstrate that interleukin 6 induces both WASF3 expression and phosphoactivation in breast and prostate cancer cell lines through the JAK2/STAT3 pathway in two different ways. First, we show that STAT3 binds directly to the WASF3 promoter and increases transcription levels, which correlates with increased migration potential. Inactivation of STAT3 with short hairpin RNA, dominant negative constructs or S3I-201 leads to reduced WASF3 levels and reduced migration. Second, we have shown that JAK2, while activating STAT3, also interacts with and activates WASF3. Inhibition of JAK2 with short hairpin RNA or AG490 leads to loss of migration due to reduced WASF3 activation levels and prevention of its membrane localization. Together, these results define a novel signaling network whereby JAK2/STAT3 signaling creates a feed-forward loop to raise activated WASF3 levels that promote cancer cell motility.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

ATAD3A mediates activation of RAS-independent mitochondrial ERK1/2 signaling, favoring head and neck cancer development

Liwei Lang, Reid Loveless, Juan Dou, Tiffany Lam, Alex Chen, Fang Wang, Li Sun, Jakeline Juarez, Zhaohui Steve Qin, Nabil F. Saba, Chloe Shay, Yong Teng

Summary: Targeting mitochondrial oncoproteins presents a new concept for effective cancer therapeutics. In this study, the researchers focused on ATAD3A and its impact on head and neck squamous cell carcinoma (HNSCC). They found that ATAD3A is highly expressed in HNSCC tissues and cell lines, and loss of ATAD3A expression suppresses HNSCC cell growth and leads to tumor regression. Mechanistically, they discovered that ATAD3A interacts with ERK1/2 in the mitochondria of HNSCC cells and this interaction is essential for the activation of mitochondrial ERK1/2 signaling. Most importantly, they showed that targeting ATAD3A in combination with RAS inhibitor treatment has a more significant tumor suppression effect. These findings highlight the potential of ATAD3A and RAS signaling as targets for HNSCC therapeutics.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2022)

Article Oncology

The Quest to Eradicate HPV-Related Oropharyngeal Carcinoma: An Opportunity Not to Miss

Chloe S. Lalonde, Yong Teng, Barbara A. Burtness, Robert L. Ferris, Rafi Ahmed, Nabil F. Saba

Summary: This article provides an overview of the necessary elements to eliminate oropharyngeal squamous cell carcinoma, including improved vaccine uptake, universal vaccination effort, and implementation of novel therapeutics to cure existing disease.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2022)

Article Oncology

Targeting Angiogenesis in Squamous Cell Carcinoma of the Head and Neck: Opportunities in the Immunotherapy Era

Nabil F. Saba, Pooja Vijayvargiya, Jan B. Vermorken, Juan P. Rodrigo, Stefan M. Willems, Nina Zidar, Remco de Bree, Antti Maekitie, Greg T. Wolf, Athanassios Argiris, Yong Teng, Alfio Ferlito

Summary: Therapies for squamous cell carcinomas of the head and neck are evolving rapidly, with the inclusion of immunotherapy and anti-angiogenic therapies. This review article explores the utility of anti-VEGF therapies on SCCHN and its interaction with the immune environment. The correlation between VEGF and the progression of SCCHN is strong, with nearly 90% of these cancers expressing VEGF.

CANCERS (2022)

Review Biochemistry & Molecular Biology

The Potential Therapeutic Impact of Metformin in Glioblastoma Multiforme

Mehdi Sanati, Samaneh Aminyavari, Hamid Mollazadeh, Ali Motamed-Sanaye, Bahram Bibak, Elmira Mohtashami, Yong Teng, Amir R. R. Afshari, Amirhossein Sahebkar

Summary: This research reviewed the literature to assess the connection between metformin's anticancer properties and the development of glioblastoma multiforme (GBM). The comprehensive review found that metformin not only inhibits tumor growth by activating the AMPK pathway, but also induces cell apoptosis, inhibits cell proliferation and metastasis, and enhances chemo-radio-sensitizing behavior against GBM through other mechanisms. Further research is needed to explore the potential of metformin-based therapeutics for GBM and the challenges they may face.

CURRENT MEDICINAL CHEMISTRY (2023)

Article Oncology

Mediation of PKM2-dependent glycolytic and non-glycolytic pathways by ENO2 in head and neck cancer development

Lixia Gao, Fan Yang, Dianyong Tang, Zhigang Xu, Yan Tang, Donglin Yang, Deping Sun, Zhongzhu Chen, Yong Teng

Summary: This study reveals that ENO2 is highly expressed in head and neck squamous cell carcinoma (HNSCC) and promotes cell proliferation and glycolysis by controlling PKM2 protein stability and nuclear translocation. Treatment with the ENO inhibitor AP-III-a4 significantly induces HNSCC remission in a preclinical mouse model.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2023)

Article Oncology

Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States

Fan Yang, Chloe Shay, Marin Abousaud, Chris Tang, Yamin Li, Zhaohui Qin, Nabil F. Saba, Yong Teng

Summary: This study analyzes immune-related adverse events (irAEs) associated with seven FDA-approved immune checkpoint inhibitors (ICIs) in cancer treatment, revealing the pattern of toxicity burden among patients. The findings highlight that irAEs related to anti-PD-1 ICIs require fewer hospital care resources compared to anti-PD-L1 and anti-CTLA-4 ICIs. Age and sex have specific impacts on tissue and organ toxicities of ICIs.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2023)

Article Biochemistry & Molecular Biology

CDK5RAP3, a key defender of udder, modulates NLRP3 inflammasome activation by regulating autophagolysosome degradation in S. agalactiae-infected mastitis

Hongchen Yan, Tianci Zhou, Yongsheng Wang, Zhengcheng Liu, Ilyas Ali, Le Sheng, Qiang Jiang, Tao Li, Minghui Xiang, Ping Li, Wei Zhang, Yong Teng, Honglin Li, Yang Liu, Yafei Cai

Summary: Streptococcus agalactiae is a major pathogen causing mastitis in animals, but its specific pathogenic mechanisms and regulatory factors are largely unknown. Our study revealed that the downregulation of CDK5RAP3 in mastitis caused by S. agalactiae triggers inflammasome activation and inhibits autophagolysosome degradation, leading to inflammation and cell death. This study sheds light on the interaction between autophagy and immune responses and provides new insights for the development of clinical drugs to cure S. agalactiae mastitis.

INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES (2023)

Editorial Material Biochemistry & Molecular Biology

Remodeling of Mitochondria in Cancer and Other Diseases

Yong Teng

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Review Oncology

Harnessing cancer stem cell-derived exosomes to improve cancer therapy

Jianqiang Yang, Yong Teng

Summary: Cancer stem cells (CSCs) are important seeds for tumor development and progression. Exosomes derived from CSCs play a significant role in various aspects of cancer. Understanding the characteristics and function of CSC-derived exosomes can potentially lead to the development of new clinical tools and therapies for cancer treatment.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2023)

Article Oncology

Loss of Ufl1/Ufbp1 in hepatocytes promotes liver pathological damage and carcinogenesis through activating mTOR signaling

Fanghui Chen, Le Sheng, Tianci Zhou, Li Yan, Reid Loveless, Honglin Li, Yong Teng, Yafei Cai

Summary: Ufl1 and Ufbp1 play a role in preventing liver fibrosis, steatohepatitis and hepatocellular carcinoma (HCC) development by inhibiting the mTOR pathway.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2023)

Article Biochemistry & Molecular Biology

Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial

Nabil F. Saba, Conor E. Steuer, Asari Ekpenyong, Ashley McCook-Veal, Kelly Magliocca, Mihir Patel, Nicole C. Schmitt, William Stokes, James E. Bates, Soumon Rudra, Jill Remick, Mark McDonald, Marin Abousaud, Aik Choon Tan, Muhammad Zaki Hidayatullah Fadlullah, Ritu Chaudhary, Jameel Muzaffar, Kedar Kirtane, Yuan Liu, Georgia Z. Chen, Dong M. Shin, Yong Teng, Christine H. Chung

Summary: PD-1 therapy is standard treatment for recurrent metastatic head and neck squamous cell carcinoma. The combination of Pembrolizumab and Cabozantinib shows promising clinical activity. Further research is needed.

NATURE MEDICINE (2023)

Review Oncology

Novel Immunotherapeutic Approaches to Treating HPV-Related Head and Neck Cancer

Nabil F. F. Saba, Saagar Pamulapati, Bhamini Patel, Mayur Mody, Primoz Strojan, Robert Takes, Antti A. A. Maekitie, Oded Cohen, Pia Pace-Asciak, Jan B. B. Vermorken, Carol Bradford, Arlene Forastiere, Yong Teng, Andreas Wieland, Alfio Ferlito

Summary: Head and neck cancer (HNC) is a common malignancy, with oropharyngeal squamous cell carcinoma (OPSCC) being the majority of cases. The incidence of HPV-related OPSCC, caused by human papillomavirus (HPV), is increasing rapidly. Immunotherapy has shown promise in managing recurrent and metastatic HNC, leading to interest in its application for HPV-related OPSCC. This review focuses on the immune characteristics and potential for immunotherapy in this virus-driven cancer.

CANCERS (2023)

Review Biochemistry & Molecular Biology

Iron, Ferroptosis, and Head and Neck Cancer

Yong Teng, Lixia Gao, Antti A. Makitie, Ewa Florek, Agata Czarnywojtek, Nabil F. Saba, Alfio Ferlito

Summary: This review discusses the relationship between ferroptosis and head and neck cancer treatment, including its conceptual framework, mechanism, functional aspects, and implications for tumor therapy. In addition, strategies for improving the efficacy of head and neck cancer treatment through modulation of ferroptosis are summarized.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Multidisciplinary Sciences

The mitochondrial fusion protein OPA1 is dispensable in the liver and its absence induces mitohormesis to protect liver from drug-induced injury

Hakjoo Lee, Tae Jin Lee, Chad A. Galloway, Wenbo Zhi, Wei Xiao, Karen L. de Mesy Bentley, Ashok Sharma, Yong Teng, Hiromi Sesaki, Yisang Yoon

Summary: This study reveals that OPA1 is dispensable in the liver and its deletion induces a mitohormesis response that protects the liver from drug toxicity and enhances liver resilience.

NATURE COMMUNICATIONS (2023)

Article Oncology

Adaptive c-Met-PLXDC2 Signaling Axis Mediates Cancer Stem Cell Plasticity to Confer Radioresistance-associated Aggressiveness in Head and Neck Cancer

Liwei Lang, Fanghui Chen, Yamin Li, Chloe Shay, Fan Yang, Hancai Dan, Zhuo G. Chen, Nabil F. Saba, Yong Teng

Summary: Radiotherapy is essential for the treatment of head and neck squamous cell carcinoma (HNSCC), but radioresistance remains a major obstacle. This study shows that radioresistant HNSCC cells exhibit increased aggressiveness and that upregulation of c-Met phosphorylation is a critical mechanism for radioresistance. The study also reveals that c-Met exacerbates radioresistance-associated aggressiveness, but its genetic knockdown and pharmacologic inactivation suppress it. Mechanistically, c-Met upregulation promotes the expression of PLXDC2, which leads to epithelial-mesenchymal transition (EMT) induction and enrichment of cancer stem cells (CSCs), resulting in radioresistance. Depletion of PLXDC2 overcomes c-Met-mediated radioresistance. Therapeutically, the addition of a selective c-Met inhibitor to radiation induces tumor shrinkage and limits tumor metastasis in a mouse model. These findings provide insights into radioresistance-associated aggressiveness and suggest a potential therapeutic strategy for HNSCC patients.

CANCER RESEARCH COMMUNICATIONS (2023)

暂无数据